Nathalie Leroy, MD
Family Medicine · Miami, FLNPI 1811206535
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 206 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Viiv Healthcare Company at 33.1% of the total. 2025 is the largest year on record at $1,263, 3.7 times the $344 reported in 2019.
Across 206 payments — averaging $21.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$1K
- Gilead$596
- Merck$393
- Amgen$323
- Amneal Pharmaceuticals LLC$182
- AstraZeneca$181
- plus $1K from 23 others
What the payments were for
- Food & beverage$4,21997%
- Education$1393%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 69 | $1,444 |
| Gilead | 26 | $596 |
| Merck | 18 | $393 |
| Amgen | 18 | $323 |
| Amneal Pharmaceuticals LLC | 10 | $182 |
| AstraZeneca | 10 | $181 |
| Novo Nordisk | 9 | $164 |
| Shield Therapeutics Inc | 2 | $100 |
| Janssen Products, LP | 1 | $99 |
| Novartis | 4 | $87 |
| Lilly USA, LLC | 5 | $86 |
| Pfizer | 4 | $85 |
| Johnson & Johnson(2 entities) | 5 | $82 |
| Cequr Corporation | 2 | $77 |
| Madrigal Pharmaceuticals | 2 | $61 |
| Boehringer Ingelheim | 3 | $58 |
| Sanofi Pasteur Inc. | 2 | $48 |
| Abbott | 2 | $46 |
| Exact Sciences | 2 | $44 |
| GSK | 2 | $31 |
| AbbVie | 2 | $31 |
| BD | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Braintree Laboratories, Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Insulet Corporation | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $15 |
| Global Blood Therapeutics, Inc. | 1 | $12 |
How this compares
$4,358 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JulucaDolutegravir/Rilpivirine | 27 | $108,747 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 12 | $77,068 |
| OzempicSemaglutide | 44 | $60,178 |
| DovatoDolutegravir Sodium/Lamivudine | 21 | $51,503 |
| JardianceEmpagliflozin | 31 | $49,868 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 11 | $40,319 |
| TradjentaLinagliptin | 25 | $35,026 |
| FarxigaDapagliflozin Propanediol | 22 | $32,375 |
| JanuviaSitagliptin Phosphate | 22 | $27,422 |
| TrulicityDulaglutide | 21 | $27,023 |
| EliquisApixaban | 20 | $20,594 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $14,679 |
| LinzessLinaclotide | 13 | $10,710 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 15 | $4,056 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $2,767 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyJuluca, Dovato | $1,444 | $160,25048 claims |
| Boehringer IngelheimJardiance, Tradjenta | $58 | $84,89456 claims |
| Janssen Products, LPSymtuza | $99 | $77,06812 claims |
| Novo NordiskOzempic | $164 | $60,17844 claims |
| MerckJanuvia, Janumet | $393 | $42,10133 claims |
| GileadBiktarvy | $596 | $40,31911 claims |
| AstraZenecaFarxiga, Symbicort | $181 | $35,14234 claims |
| Lilly USA, LLCTrulicity | $86 | $27,02321 claims |
| PfizerEliquis | $85 | $20,59420 claims |
| AbbVieLinzess | $31 | $10,71013 claims |
| GSKArexvy | $31 | $4,05615 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $182 | $27734 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Miami
- Clifford KinderMiami$75K
- Robert GoubeauxMiami$67K
- Vanessa RojasMiami$50K
- Michelle PowellMiami$34K
- Ana EloseguiMiami$32K
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.